Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + lobeglitazone
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dapagliflozin + lobeglitazone is a combination therapy used for the treatment of type 2 diabetes mellitus (T2DM). This combination brings together two distinct mechanisms of action to improve glycemic control. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor that works by increasing urinary glucose excretion, while lobeglitazone is a thiazolidinedione (TZD) that improves insulin sensitivity. Clinical studies have shown that this combination therapy results in significant reductions in HbA1c levels, body weight, visceral fat area, and blood pressure in patients with inadequately controlled T2DM. The combination is particularly effective when added to metformin therapy.
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on dapagliflozin + lobeglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + lobeglitazone.